Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays

Masatoshi Wakui, Yuta Fujimori, Shoko Nakamura, Yoshino Kondo, Yuko Kuroda, Shusaku Oka, Terumichi Nakagawa, Hisako Katagiri, Mitsuru Murata

Research output: Contribution to journalArticle

Abstract

Aims Bivalent direct thrombin inhibitors (DTIs), hirudin and bivalirudin, bind to the active site and exosite 1 of thrombin irreversibly and reversibly, respectively. The present study aims to assess in vitro effects of hirudin and bivalirudin through clot waveform analysis (CWA) and enzyme kinetics in coagulation assays. Methods The pooled normal plasma and its dilutions were spiked with hirudin or bivalirudin. The activated partial thromboplastin time (APTT) assay and the Clauss fibrinogen assay were performed using the CS-5100 (Sysmex). The APTT-CWA data were automatically gained by the CS-5100 programme. Results In APTT-CWA, the maximum coagulation velocity, acceleration and deceleration were decreased dependently on the drug concentrations, demonstrating evidence for the blockade of thrombin-positive feedback by hirudin or bivalirudin. The Hill plot analysis was applied to the dose-dependent curves in bivalirudin. The Hill coefficients were greater than 1, showing positive anticoagulant cooperativity. Regarding the dose-dependent curves in hirudin, all the parameters dropped to almost zero without making an asymptotic line. In the Clauss fibrinogen assay, the Lineweaver-Burk plots demonstrated that both drugs exhibit mixed inhibition mimicking uncompetitive binding. The Dixon plots in bivalirudin were linear and supported the inhibition type described above. The Dixon plots in hirudin were non-linear and inappropriate to use for determination of the inhibition type. In addition, the inverse function of the clotting time appeared to drop to zero without making an asymptotic line, suggesting complete loss of thrombin activity by irreversible binding. Conclusions The results provide insights into anticoagulation with bivalent DTIs.

Original languageEnglish
Pages (from-to)817-824
Number of pages8
JournalJournal of Clinical Pathology
Volume72
Issue number12
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Hirudins
Antithrombins
Partial Thromboplastin Time
Enzymes
Thrombin
Fibrinogen
Deceleration
Pharmaceutical Preparations
Anticoagulants
bivalirudin
Catalytic Domain

Keywords

  • APTT assay
  • bivalent direct thrombin inhibitors
  • clauss fibrinogen assay
  • clot waveform analysis
  • enzyme kinetics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays. / Wakui, Masatoshi; Fujimori, Yuta; Nakamura, Shoko; Kondo, Yoshino; Kuroda, Yuko; Oka, Shusaku; Nakagawa, Terumichi; Katagiri, Hisako; Murata, Mitsuru.

In: Journal of Clinical Pathology, Vol. 72, No. 12, 01.12.2019, p. 817-824.

Research output: Contribution to journalArticle

Wakui, Masatoshi ; Fujimori, Yuta ; Nakamura, Shoko ; Kondo, Yoshino ; Kuroda, Yuko ; Oka, Shusaku ; Nakagawa, Terumichi ; Katagiri, Hisako ; Murata, Mitsuru. / Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays. In: Journal of Clinical Pathology. 2019 ; Vol. 72, No. 12. pp. 817-824.
@article{71a028c1c79b46e79fbe166e33c695b7,
title = "Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays",
abstract = "Aims Bivalent direct thrombin inhibitors (DTIs), hirudin and bivalirudin, bind to the active site and exosite 1 of thrombin irreversibly and reversibly, respectively. The present study aims to assess in vitro effects of hirudin and bivalirudin through clot waveform analysis (CWA) and enzyme kinetics in coagulation assays. Methods The pooled normal plasma and its dilutions were spiked with hirudin or bivalirudin. The activated partial thromboplastin time (APTT) assay and the Clauss fibrinogen assay were performed using the CS-5100 (Sysmex). The APTT-CWA data were automatically gained by the CS-5100 programme. Results In APTT-CWA, the maximum coagulation velocity, acceleration and deceleration were decreased dependently on the drug concentrations, demonstrating evidence for the blockade of thrombin-positive feedback by hirudin or bivalirudin. The Hill plot analysis was applied to the dose-dependent curves in bivalirudin. The Hill coefficients were greater than 1, showing positive anticoagulant cooperativity. Regarding the dose-dependent curves in hirudin, all the parameters dropped to almost zero without making an asymptotic line. In the Clauss fibrinogen assay, the Lineweaver-Burk plots demonstrated that both drugs exhibit mixed inhibition mimicking uncompetitive binding. The Dixon plots in bivalirudin were linear and supported the inhibition type described above. The Dixon plots in hirudin were non-linear and inappropriate to use for determination of the inhibition type. In addition, the inverse function of the clotting time appeared to drop to zero without making an asymptotic line, suggesting complete loss of thrombin activity by irreversible binding. Conclusions The results provide insights into anticoagulation with bivalent DTIs.",
keywords = "APTT assay, bivalent direct thrombin inhibitors, clauss fibrinogen assay, clot waveform analysis, enzyme kinetics",
author = "Masatoshi Wakui and Yuta Fujimori and Shoko Nakamura and Yoshino Kondo and Yuko Kuroda and Shusaku Oka and Terumichi Nakagawa and Hisako Katagiri and Mitsuru Murata",
year = "2019",
month = "12",
day = "1",
doi = "10.1136/jclinpath-2019-205922",
language = "English",
volume = "72",
pages = "817--824",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "12",

}

TY - JOUR

T1 - Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays

AU - Wakui, Masatoshi

AU - Fujimori, Yuta

AU - Nakamura, Shoko

AU - Kondo, Yoshino

AU - Kuroda, Yuko

AU - Oka, Shusaku

AU - Nakagawa, Terumichi

AU - Katagiri, Hisako

AU - Murata, Mitsuru

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Aims Bivalent direct thrombin inhibitors (DTIs), hirudin and bivalirudin, bind to the active site and exosite 1 of thrombin irreversibly and reversibly, respectively. The present study aims to assess in vitro effects of hirudin and bivalirudin through clot waveform analysis (CWA) and enzyme kinetics in coagulation assays. Methods The pooled normal plasma and its dilutions were spiked with hirudin or bivalirudin. The activated partial thromboplastin time (APTT) assay and the Clauss fibrinogen assay were performed using the CS-5100 (Sysmex). The APTT-CWA data were automatically gained by the CS-5100 programme. Results In APTT-CWA, the maximum coagulation velocity, acceleration and deceleration were decreased dependently on the drug concentrations, demonstrating evidence for the blockade of thrombin-positive feedback by hirudin or bivalirudin. The Hill plot analysis was applied to the dose-dependent curves in bivalirudin. The Hill coefficients were greater than 1, showing positive anticoagulant cooperativity. Regarding the dose-dependent curves in hirudin, all the parameters dropped to almost zero without making an asymptotic line. In the Clauss fibrinogen assay, the Lineweaver-Burk plots demonstrated that both drugs exhibit mixed inhibition mimicking uncompetitive binding. The Dixon plots in bivalirudin were linear and supported the inhibition type described above. The Dixon plots in hirudin were non-linear and inappropriate to use for determination of the inhibition type. In addition, the inverse function of the clotting time appeared to drop to zero without making an asymptotic line, suggesting complete loss of thrombin activity by irreversible binding. Conclusions The results provide insights into anticoagulation with bivalent DTIs.

AB - Aims Bivalent direct thrombin inhibitors (DTIs), hirudin and bivalirudin, bind to the active site and exosite 1 of thrombin irreversibly and reversibly, respectively. The present study aims to assess in vitro effects of hirudin and bivalirudin through clot waveform analysis (CWA) and enzyme kinetics in coagulation assays. Methods The pooled normal plasma and its dilutions were spiked with hirudin or bivalirudin. The activated partial thromboplastin time (APTT) assay and the Clauss fibrinogen assay were performed using the CS-5100 (Sysmex). The APTT-CWA data were automatically gained by the CS-5100 programme. Results In APTT-CWA, the maximum coagulation velocity, acceleration and deceleration were decreased dependently on the drug concentrations, demonstrating evidence for the blockade of thrombin-positive feedback by hirudin or bivalirudin. The Hill plot analysis was applied to the dose-dependent curves in bivalirudin. The Hill coefficients were greater than 1, showing positive anticoagulant cooperativity. Regarding the dose-dependent curves in hirudin, all the parameters dropped to almost zero without making an asymptotic line. In the Clauss fibrinogen assay, the Lineweaver-Burk plots demonstrated that both drugs exhibit mixed inhibition mimicking uncompetitive binding. The Dixon plots in bivalirudin were linear and supported the inhibition type described above. The Dixon plots in hirudin were non-linear and inappropriate to use for determination of the inhibition type. In addition, the inverse function of the clotting time appeared to drop to zero without making an asymptotic line, suggesting complete loss of thrombin activity by irreversible binding. Conclusions The results provide insights into anticoagulation with bivalent DTIs.

KW - APTT assay

KW - bivalent direct thrombin inhibitors

KW - clauss fibrinogen assay

KW - clot waveform analysis

KW - enzyme kinetics

UR - http://www.scopus.com/inward/record.url?scp=85075665600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075665600&partnerID=8YFLogxK

U2 - 10.1136/jclinpath-2019-205922

DO - 10.1136/jclinpath-2019-205922

M3 - Article

C2 - 31366633

AN - SCOPUS:85075665600

VL - 72

SP - 817

EP - 824

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 12

ER -